Neurocrine Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	478.6	341.3	249.7	154.5	89.6
Depreciation & Amortization	30.1	27.1	21.3	15.6	10.9
Stock-Based Compensation	217.9	195.5	194.3	173.1	134.2
Other Adjustments	184.9	50.7	-103.6	63.6	5.1
Change in Receivables	-210.5	-39.8	-89.3	-162.2	-28.4
Changes in Inventories	-15.3	-19.1	5.4	-2.6	-2.5
Changes in Accounts Payable	160.2	43.4	49	114.6	56.8
Changes in Income Taxes Payable	-18.8	50.3	91.6	-	-
Changes in Other Operating Activities	-44.4	-54	-28.5	-17.2	-9.2
Operating Cash Flow	782.7	595.4	389.9	339.4	256.5
Operating Cash Flow Growth	31.46%	52.71%	14.88%	32.32%	12.25%
Capital Expenditures	-34	-38.2	-28.3	-16.5	-23.4
Purchases of Investments	-1,320	-1,056	-1,411	-628.9	-804.7
Proceeds from Sale of Investments	1,089	967.5	972.4	511	697.9
Payments for Business Acquisitions	-	-	-	-42.7	-
Investing Cash Flow	-264.4	-126.8	-467.1	-177.1	-130.2
Long-Term Debt Repaid	-	-308.8	-	-279	-0.1
Net Long-Term Debt Issued (Repaid)	-	-308.8	-	-279	-0.1
Issuance of Common Stock	129.4	122.1	65.3	44.7	27.5
Repurchase of Common Stock	-167.7	-300	-	-	-
Net Common Stock Issued (Repurchased)	-38.3	-177.9	65.3	44.7	27.5
Financing Cash Flow	-38.3	-486.7	65.3	-234.3	27.4
Effect of Exchange Rate Changes on Cash and Cash Equivalents	-	-	0.3	-1.3	-
Net Cash Flow	480	-18.1	-11.6	-73.3	153.7
Free Cash Flow	748.7	557.2	361.6	322.9	233.1
Free Cash Flow Growth	34.37%	54.09%	11.98%	38.52%	7.12%
FCF Margin	26.17%	23.66%	19.16%	21.69%	20.56%
Free Cash Flow Per Share	7.30	5.37	3.58	3.26	2.38
Levered Free Cash Flow	556.4	42	360.2	-30.6	122.1
Unlevered Free Cash Flow	497.85	410.14	299.15	273.75	123.17

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.